ERBB2 and breast cancer: Trastuzumab was once hypothesized to work in early-stage BC with minimum levels of HER2 expression: other than blocking the HER2 growth signaling pathway, trastuzumab also causes antibody-dependent cellular cytotoxicity (ADCC).